Inventiva (IVA) Cash from Operations (2019 - 2025)
Inventiva (IVA) posted quarterly Cash from Operations of 121629068.47 for Q2 2025, up 333.64% year-over-year from 28048563.88 in Q2 2024, and up 333.64% quarter-over-quarter from 52058899.21 in Q2 2024.
Inventiva (IVA) Cash from Operations (2019 - 2025) Analysis & Trends
Inventiva's Cash from Operations history runs 6 years deep, the most recent figure standing at 121629068.47 for Q2 2025.
- In Q2 2025, Cash from Operations rose 333.64% year-over-year to 121629068.47; the TTM figure through Jun 2025 stood at 15458233.26 (up 112.0% YoY), while the FY2025 annual figure was 122108164.69, down 32.98% from the prior year.
- Cash from Operations for Q2 2025 stood at 121629068.47, up from 52058899.21 in the prior quarter.
- The five-year high for Cash from Operations was 121629068.47 in Q2 2025, with the low at 52058899.21 in Q2 2024.
- The 4-year median for Cash from Operations is 22641473.06 (2021), against an average of 4433352.46.
- The sharpest annual moves came in 2021 and 2025: Cash from Operations tumbled 265.59% in 2021, then soared 333.64% in 2025.
- Inventiva's Cash from Operations stood at 22641473.06 in 2021, then declined by 18.15% to 26751906.17 in 2022, then tumbled by 94.6% to 52058899.21 in 2024, then soared by 333.64% to 121629068.47 in 2025.
- Business Quant data shows IVA's Cash from Operations at 121629068.47 in Q2 2025, 52058899.21 in Q2 2024, and 26751906.17 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 121.63 Mn |
| Jun 30, 2025 | 121.63 Mn |
| Jun 30, 2024 | -52.06 Mn |
| Jun 30, 2024 | -52.06 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Sep 22, 2022 | -27.36 Mn |
| Sep 22, 2022 | -27.36 Mn |
| Dec 31, 2021 | -22.64 Mn |
| Dec 31, 2021 | -22.64 Mn |
| Jun 30, 2021 | -14.46 Mn |
| Jun 30, 2021 | -14.46 Mn |
| Mar 31, 2021 | -9.39 Mn |
| Mar 31, 2021 | -9.39 Mn |
| Dec 31, 2020 | -8.55 Mn |
| Dec 31, 2020 | -8.55 Mn |
| Jun 30, 2020 | -3.96 Mn |
| Jun 30, 2020 | -3.96 Mn |
| Mar 31, 2020 | -3.95 Mn |
| Mar 31, 2020 | -3.95 Mn |